secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001847903-25-000081
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa appoints Raphael Deferiere as Chief Accounting Officer
---------------------------------------------------------------

- Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.
- Base salary of $400,000; annual bonus target 35% of base; option for 165,000 ADSs.
- Option vests 25% at one year, then 36 equal monthly installments.
- Mr. Deferiere was an Assurance Partner at Ernst & Young LLP (July 2017 – May 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/0001847903-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000081/cnta-20250527.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer